Global Menin Inhibitor Drugs Clinical Trials & Insight Report 2023 Featuring Biomea Fusion, BioNova, Daiichi Sankyo, Easton, Eilean Therapeutics, HitGen, Janssen, and Sumitomo
15 déc. 2023 04h48 HE
|
Research and Markets
Dublin, Dec. 15, 2023 (GLOBE NEWSWIRE) -- The "Global Menin Inhibitor Drugs Clinical Trials & Future Opportunity Insight 2023" report has been added to ResearchAndMarkets.com's offering. ...
Global MCL1 Inhibitor Drug Clinical Trials & Commercialization Research Study 2023: Focus on 12 Drugs in Clinical Trials and Synribo, the 1 Commercially Approved MCL1 Inhibitor Drug
15 déc. 2023 04h43 HE
|
Research and Markets
Dublin, Dec. 15, 2023 (GLOBE NEWSWIRE) -- The "Global MCL1 Inhibitor Drug Clinical Trials & Commercialization Opportunity Insights 2023" report has been added to ResearchAndMarkets.com's...
Adaptive Research Marks Milestone Growth with First Theranostics Center in Partnership with Florida Theranostics
13 déc. 2023 08h13 HE
|
Adaptive Research Inc
Florida Theranostics joins Adaptive Research Inc's network of community trial sites.
Global Biobanks Strategic Research Report 2023: Market to Reach $131.1 Billion by 2030 - Growing Research Focus on Regenerative Medicine Expands Opportunities
11 déc. 2023 11h48 HE
|
Research and Markets
Dublin, Dec. 11, 2023 (GLOBE NEWSWIRE) -- The "Biobanks - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Biobanks Market to Reach $131.1 Billion...
Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)
10 déc. 2023 19h30 HE
|
Novartis Pharma AG
APPLY-PNH extension data show that continuous Fabhalta® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to...
Ivy Brain Tumor Center Announces Promising Data for Niraparib in Phase 0/2 Glioblastoma Clinical Trial
17 nov. 2023 08h00 HE
|
Ivy Brain Tumor Center
Phoenix, AZ, Nov. 17, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announces promising results from a Phase 0/2 trial of niraparib in patients with newly...
Global Active Pharmaceutical Ingredient CDMO Market to Reach $156.3 Billion by 2030, Driven by Rising R&D Investments and Demand for Generic Drugs
10 nov. 2023 08h03 HE
|
Research and Markets
Dublin, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The "Active Pharmaceutical Ingredient CDMO Market Size, Share & Trends Analysis Report By Product (Highly Potent API, Antibody Drug Conjugate), By...
CORRECTION – Data Logistics: a generation-defining advancement in healthcare
07 nov. 2023 15h15 HE
|
Datavant
Datavant brings data logistics to healthcare, working to fix the broken health data supply chain.
Data Logistics: a generation-defining advancement in healthcare
07 nov. 2023 06h00 HE
|
Datavant
Datavant brings data logistics to healthcare, working to fix the broken health data supply chain.
Ivy Center Announces First Patient Treated in Targeted Phase 0/1 Clinical Trial for High-Grade Glioma
06 nov. 2023 10h00 HE
|
Ivy Brain Tumor Center
Phoenix, AZ, Nov. 06, 2023 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute announced the first patient has been treated in a novel Phase 0/1 clinical trial of...